Predicting ALK cancer treatment outcomes using digital pathology
Part of Cancer, Lungs & breathing clinical trials.
This study uses a computer to analyze digital images of tumor tissue from people with a certain type of lung cancer (ALK-positive non-small cell lung cancer). It aims to see if the computer can predict how well newer-generation ALK inhibitors work in these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have an active cancer diagnosis
- Your lung cancer is a type called non-small cell lung cancer (NSCLC)
- Your lung cancer cells have a specific change called an ALK mutation (ALK-positive)
- You have been treated with a newer ALK-targeting drug (like alectinib, lorlatinib, brigatinib, or ceritinib) as your first ALK inhibitor therapy
- You have given general or specific consent for your medical information to be used in this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with ALK-positive non-small cell lung cancer do not respond to ALK inhibitor drugs. By studying tissue and blood samples, researchers hope to find reasons for resistance and improve future treatments.
This study tests an AI tool that looks at your tumor tissue images to predict certain gene changes (EGFR, ALK, ROS1) without needing extra tests. If you have non-small cell lung cancer and haven't had treatment yet, this could help guide your care.
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This study uses artificial intelligence to predict how well EGFR-targeted therapy will work for people with certain lung cancers. It looks at your imaging and genetic information to help guide treatment.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Hear when a new ALK-positive Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.